Debt (Details Narrative) |
12 Months Ended | ||||||||
|---|---|---|---|---|---|---|---|---|---|
Feb. 01, 2026 |
Sep. 09, 2025
USD ($)
$ / shares
shares
|
Jul. 30, 2025
USD ($)
Integer
$ / shares
|
Jul. 28, 2025
USD ($)
$ / shares
|
May 13, 2025 |
May 30, 2024
USD ($)
$ / shares
shares
|
Dec. 31, 2025
USD ($)
shares
|
Dec. 31, 2024
USD ($)
|
Aug. 01, 2025
USD ($)
|
|
| Short-Term Debt [Line Items] | |||||||||
| Convertible debt | $ 195,324,000 | ||||||||
| Discount amount | $ 8,401,000 | $ 5,752,000 | |||||||
| Interest rate | 12.70% | 12.30% | |||||||
| Interest expense | $ 14,400,000 | $ 10,300,000 | |||||||
| Discount amount | $ 2,700,000 | $ 1,300,000 | |||||||
| Warrants issued | shares | 6,422,560,000 | ||||||||
| Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate | 0.00% | 0.00% | |||||||
| Final fee | $ 5,850,000 | $ 4,500,000 | |||||||
| Fair value of note payable | 160,200,000 | ||||||||
| Amended and Restated Loan Agreement [Member] | Innovatus Life Sciences [Member] | |||||||||
| Short-Term Debt [Line Items] | |||||||||
| Contingent loan | $ 120,000,000.0 | ||||||||
| Amendment fee payable | $ 100,000 | ||||||||
| Funded loan amount | $ 100,000,000 | ||||||||
| Costs associated with new borrowings | $ 2,400,000 | ||||||||
| Final fee percentage | 4.50% | ||||||||
| Final fee | $ 4,500,000 | ||||||||
| Warrant or right, reason for issuance, description | 2.50% | ||||||||
| Amended and Restated Loan Agreement [Member] | Innovatus Life Sciences [Member] | Warrant [Member] | |||||||||
| Short-Term Debt [Line Items] | |||||||||
| Warrants exercise price per share | $ / shares | $ 14.84 | $ 14.84 | |||||||
| Warrants issued | shares | 50,537 | 103,876 | |||||||
| Fair value of warrants | $ 1,200,000 | ||||||||
| Amended and Restated Loan Agreement [Member] | Innovatus Life Sciences [Member] | Term D Loan [Member] | |||||||||
| Short-Term Debt [Line Items] | |||||||||
| Disbursement loan amount | $ 30,000,000.0 | ||||||||
| Net proceeds from loan | $ 27,700,000 | ||||||||
| Debt final fee percentage | 4.50% | ||||||||
| Funded loan amount | $ 1,400,000 | ||||||||
| Amended and Restated Loan Agreement [Member] | Innovatus Life Sciences [Member] | Term E Loan [Member] | |||||||||
| Short-Term Debt [Line Items] | |||||||||
| Contingent loan | 50,000,000.0 | ||||||||
| Funded loan amount | 50,000,000.0 | ||||||||
| Amended and Restated Loan Agreement [Member] | Innovatus Life Sciences [Member] | Term E Two Loan [Member] | |||||||||
| Short-Term Debt [Line Items] | |||||||||
| Contingent loan | 100,000,000.0 | ||||||||
| Amended and Restated Loan Agreement [Member] | Innovatus Life Sciences [Member] | Term F Loan [Member] | |||||||||
| Short-Term Debt [Line Items] | |||||||||
| Contingent loan | 40,000,000.0 | ||||||||
| Funded loan amount | $ 45,000,000.0 | ||||||||
| Amended and Restated Loan Agreement [Member] | Innovatus Life Sciences [Member] | Term F Two Loan [Member] | |||||||||
| Short-Term Debt [Line Items] | |||||||||
| Contingent loan | 45,000,000.0 | ||||||||
| Amended and Restated Loan Agreement [Member] | Innovatus Life Sciences [Member] | Term G Loan [Member] | |||||||||
| Short-Term Debt [Line Items] | |||||||||
| Contingent loan | 150,000,000.0 | ||||||||
| Amended and Restated Loan Agreement [Member] | Innovatus Life Sciences [Member] | Term A Loan [Member] | |||||||||
| Short-Term Debt [Line Items] | |||||||||
| Interest rate | 20.00% | ||||||||
| Funded loan amount | $ 16,800,000 | ||||||||
| Common stock price per share | $ / shares | $ 10.00 | ||||||||
| Amended and Restated Loan Agreement [Member] | Innovatus Life Sciences [Member] | Term B Loan [Member] | |||||||||
| Short-Term Debt [Line Items] | |||||||||
| Funded loan amount | $ 21,500,000 | ||||||||
| Amended and Restated Loan Agreement [Member] | Innovatus Life Sciences [Member] | Term C Loan [Member] | |||||||||
| Short-Term Debt [Line Items] | |||||||||
| Funded loan amount | $ 61,700,000 | ||||||||
| Prior Loan Agreement [Member] | Innovatus Life Sciences [Member] | |||||||||
| Short-Term Debt [Line Items] | |||||||||
| Common stock price per share | $ / shares | $ 14.40 | ||||||||
| Issuance of common stock in an ATM offering, net of issuance costs, shares | shares | 26,042 | ||||||||
| Note Underwriting Agreement [Member] | July 2025 Convertible Notes Offering [Member] | |||||||||
| Short-Term Debt [Line Items] | |||||||||
| Debt instrument principal amount | $ 175,000,000.0 | $ 201,300,000 | |||||||
| Conversion rate | 19.4932 | ||||||||
| Principal amount | $ 1,000 | ||||||||
| Conversion price | $ / shares | $ 51.30 | ||||||||
| Redemption description | The Notes will be redeemable, in whole or in part (subject to certain limitations described below), at the Company’s option at any time, and from time to time, on a redemption date on or after August 6, 2029 and on or before the 51st scheduled trading day immediately before the maturity date, at a cash redemption price equal to the principal amount of the Notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date, but only if the last reported sale price per share of the common stock exceeds 130% of the conversion price on (i) each of at least 20 trading days, whether or not consecutive, during the 30 consecutive trading days ending on, and including, the trading day immediately before the date the Company sends the related redemption notice; and (ii) the trading day immediately before the date the Company sends such notice. However, the Company may not redeem less than all of the outstanding Notes unless at least $50.0 million aggregate principal amount of Notes are outstanding and not called for redemption as of the time the Company sends the related redemption notice. In addition, calling any Note for redemption will constitute a Make-Whole Fundamental Change with respect to that Note, in which case the conversion rate applicable to the conversion of that Note will be increased in certain circumstances if it is converted after it is called for redemption. | ||||||||
| Trading days | Integer | 20 | ||||||||
| Consecutive trading days | Integer | 30 | ||||||||
| First Amendment description | beneficially own in excess of 4.99% of the number of shares of the Company’s common stock outstanding immediately prior to, and immediately after giving effect to, the conversion of all or any portion of the Notes; provided, that such 4.99% beneficial ownership can be increased or decreased at the discretion of the noteholder; provided further, that such limitation in no event can exceed 19.99%. | ||||||||
| Convertible debt | 195,300,000 | ||||||||
| Fair value of the Notes | $ 436,500,000 | ||||||||
| Discount amount | $ 6,400,000 | ||||||||
| Interest rate | 3.30% | ||||||||
| Interest expense | $ 2,700,000 | ||||||||
| Discount amount | $ 400,000 | ||||||||
| Note Underwriting Agreement [Member] | July 2025 Convertible Notes Offering [Member] | Subsequent Event [Member] | |||||||||
| Short-Term Debt [Line Items] | |||||||||
| Accrue interest payable rate | 2.75% | ||||||||
| Note Underwriting Agreement [Member] | July 2025 Convertible Notes Offering [Member] | Over-Allotment Option [Member] | |||||||||
| Short-Term Debt [Line Items] | |||||||||
| Debt instrument principal amount | 26,300,000 | ||||||||
| Net proceeds from offering | $ 194,900,000 | ||||||||
| Third Amendment to Amended and Restated Loan and Security Agreement [Member] | Term D Loan [Member] | |||||||||
| Short-Term Debt [Line Items] | |||||||||
| Debt Instrument, Fee Amount | $ 2,800,000 | ||||||||
| Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate | 4.10% | ||||||||
| Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate | 74.40% | ||||||||
| Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term | 10 years | ||||||||
| Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate | 0.00% | ||||||||
| Second Amendment To Amended And Restated Loan And Security Agreement [Member] | |||||||||
| Short-Term Debt [Line Items] | |||||||||
| Debt instrument principal amount | $ 180,000,000 | ||||||||
| Amendment fee payable | $ 100,000 | ||||||||
| Maturity date | May 09, 2026 | ||||||||
| Conversion percentage | 20.00% | ||||||||
| Common stock price per share | $ / shares | $ 10.00 | ||||||||
| Amount of indebtedness eligible to incur under Term D Loan | $ 30,000,000.0 | ||||||||
| Loan Agreement [Member] | |||||||||
| Short-Term Debt [Line Items] | |||||||||
| First Amendment description | (i) pay Oxford an amendment fee of less than $0.1 million on the effective date of the First Amendment, (ii) extend to March 9, 2026 the expiration date of Innovatus’ right to convert up to 20% of the outstanding principal of the Term A Loan into shares of the Company’s common stock at a price per share of $10.00, (iii) extend the expiration date of the Term D Draw Period to the earlier of (x) August 31, 2025 and (y) the occurrence of an Event of Default (as defined in the A&R Loan Agreement), (iv) update the liquidity covenant to increase the Minimum Liquidity Percentage (as defined in the First Amendment) to 50% if the Company had failed to achieve the Term D Milestone prior to June 1, 2025 and to decrease the Minimum Liquidity Percentage back to 30% if the Company subsequently achieves the Term D Milestone prior to the end of the Term D Draw Period, and (v) release Innovatus and the Lenders from any and all claims arising out of or related to the A&R Loan Agreement, the First Amendment and related documentation. | ||||||||
| Amended and Restated Loan Agreement [Member] | |||||||||
| Short-Term Debt [Line Items] | |||||||||
| Debt instrument interest rate description | the Company is entitled to make interest-only payments for thirty-six months, or up to forty-eight months if certain conditions are met. The Term Loans bear interest at a rate equal to the sum of (a) the greater of (i) the Prime Rate (as defined in the A&R Loan Agreement) or (ii) 7.75%, plus (b) 2.85%, provided that 1.0% of such interest will be payable in-kind by adding an amount equal to such 1.0% of the outstanding principal amount to the then outstanding principal balance on a monthly basis through May 31, 2027. | ||||||||